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Introduction: Genes often have multiple polymorphisms that interact with each other and the 
environment in different individuals. Variability in the opioid receptors can influence opiate 
withdrawal and dependence. In humans, A118G Single Nucleotide Polymorphisms (SNP) on 
μ-Opioid Receptor (MOR), 36 G>T in κ-Opioid Receptor (KOR), and T921C in the δ-Opioid 
Receptor (DOR) have been found to associate with substance dependence. 
Methods: To investigate the association between opioid receptors gene polymorphism and 
heroin addiction, 100 control subjects with no history of opioid use, and 100 heroin addicts (50% 
males and 50% females) in Tehran (capital of Iran), were evaluated. A118G, 36 G>T, and T921C 
SNPs on the MOR, KOR, DOR genes, respectively, were genotyped by sequencing. 
Results: We found no differences in either allele or genotype frequency for MOR, KOR and DOR 
genes SNPs between controls and subjects addicted to heroin. 
Conclusion: The relationships among polymorphisms may be important in determining the risk 
profile for complex diseases such as addiction, but opioid addiction is a multifactorial syndrome 
which is partially hereditary and partially affected by the environment. 
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1. Introduction 
hile severe social and economic 
problems will result from using 
illegal drugs in the society, patho-
genesis of addictive disorders and 
mechanisms of therapeutic strate-
gies for drug addicts have not been well understood 
yet (Mayer et al., 1997). Transition from an occasional 
user to an addict depends on the drug user, drug, and 
environment (Yuferov, Levran, Proudnikov, Nielsen, 
& Kreek, 2010). The µ-Opioid Receptor (MOR), 
κ-Opioid Receptor (KOR) and δ-Opioid Receptor 
(DOR) mediate the impact of opioids including toler-
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ance, analgesia, dependence, and reward (Stein, 2016). 
Several lines of evidence indicate that genetic varia-
tions in the MOR gene (OPRM1), KOR gene (OPRK1) 
and DOR gene (OPRD1) can influence the expression, 
structure, or function of the receptors and ultimately 
result in increased or decreased susceptibility to opi-
oid dependency (Crist, Doyle, Kampman, & Berrettini, 
2016; Sharafshah et al., 2017). 
Single nucleotide polymorphisms (SNPs) in OPRM1, 
OPRK1, and OPRD1 are candidates for their role in me-
diating differences in the opioid addiction. Genetic vari-
ation in these genes may create or function (which might 
result in receptors with altered expression) structured de-
crease or increase vulnerability to reliance on substance 
(Bond et al., 1998; Koch et al., 2000; Wang, Quillan, 
Winans, Lucas, & Sadée, 2001), and impact treatment 
response to opioid antagonists (Oslin et al., 2003). A 
number of studies have reported that A118G, in the first 
exon of the OPRM1 gene can be influential in individual 
susceptibility toward opioid dependency (Kreek, Bart, 
Lilly, Laforge, & Nielsen, 2005). Also, 36 G>T SNP at 
exon 1 of the KOR gene has been reported to contribute 
in predisposition to voluntary alcohol-drinking behavior 
in experimental animals (Saito et al., 2003). 
In humans, this SNP has been found to be substantially 
associated with a population of heroin addicts of West Eu-
ropean, Caucasian origin (Gerra et al., 2007). It has been 
reported that T921C SNP on the 3 exon OPRD1 is associ-
ated with increased substance abuse (Gelernter & Kranzler, 
2000; Mayer et al., 1997). In addition, dependence on opi-
oids is a medical and social problem in the world as well 
as Iran (Degenhardt et al., 2013; Majdzadeh et al., 2009; 
Shadnia, Soltaninejad, Heydari, Sasanian, & Abdollahi, 
2008). Thus, further research is needed to recognize genetic 
variables that contribute to the progress of opioid addiction, 
to confirm probable genetic associations and to increase the 
neurobiological understanding of opioid dependence in or-
der to find more potent analgesics with minimal unwanted 
actions. The principle objective of this research was to rec-
ognize genetic polymorphisms associated with the exclu-
sive vulnerability toward opioid addiction and reproduce 
previous research in this field. Identifying these genetic 
markers will help detect people at risk for opiate addiction 
and provide better treatment options for them. 
2. Methods 
2.1. Study subjects 
One hundred control subjects with no history of opioid 
use and one hundred heroin addicts (50% males and 50% 
females, aged 20-45 years) volunteered for the study in 
Tehran, Iran. The control group was recruited from uni-
versity students and employees while the study group 
was recruited from drug rehabilitation centers in Tehran. 
Both groups participated in the research with their writ-
ten consent. The participants were not paid and agreed 
to participate in the study voluntarily. In drug dependent 
individuals, heroin abuse was confirmed by psychiatric 
examination. Exclusion criteria included polydrug abus-
ers, utilization of other narcotics, excessive alcohol in-
take, and psychotropic factors. 
2.2. DNA extraction and PCR amplification 
 Twenty milliliters of EDTA-treated blood was obtained 
from peripheral vein of subjects and control groups. We 
used a DNA kit (Cinnagen, Tehran, Iran) for DNA ex-
traction according to the manufacturer’s protocols. Brief-
ly, lysis buffer was added to the sample and vortexed. 
Then, the precipitation solution was added to the sample 
and the solution transferred to a collection tube and cen-
trifuged at 13000 rpm. The spin column was washed and 
the DNA was eluted to a tube by elution buffer. 
2.3. Selection and genotyping of SNPs 
The SNPs A118G in exon 1 of the OPRM1 (Grösch, 
Niederberger, Lötsch, Skarke, & Geisslinger, 2001), 36 
G>T in the exon 2 of the OPRK1 (Gerra et al., 2007), 
and T921C in the exon 1 of the OPRD1 (Franke et al., 
1999) were amplified using primers provided in Table 
1. PCR amplifications were performed in 20 μL PCR 
reaction system consisting of 20 mM Tris–HCl pH 8.0, 
50 mM EDTA, 0.2 mM dNTPs, 1.5 mM MgCl2, 0.5 
μmol each primer (forward and reverse) and 2.5 units 
of Taq polymerase (Kumar, Chakraborty, & Das, 2012). 
The PCR reactions were programmed as follows. For 
OPRD, we used an initial denaturation at 95ºC for 3 min, 
40 cycles at 95ºC for 50 s, 66ºC for 90 s and 72ºC for 90 
s. The reaction was terminated by an elongation period 
at 72ºC for 6 min. For OPRM, we used an initial dena-
turation at 95ºC for 5 min, followed by 45 cycles at 95ºC 
for 10 s, 50ºC for 150 s and 72ºC for 15 s with a final 
elongation time at 72ºC for 6 min. The same annealing 
temperature was used for β-actin. For OPRK, we used 
the same program as OPRM with 43 cycles and 55ºC 
annealing temperature. PCR products were separated by 
electrophoresis in 1.5% agarose gel at 100 V. PCR prod-
ucts size (301, 300, and 294 bp for OPRM, OPRK, and 
OPRD, respectively) confirmation was performed using 
a 1% agarose gel stained by ethidium-bromide and vi-
sualized by UV light. Automated DNA sequencing was 
performed using the primer described above and the Apr-
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plied Biosystems TaqMan platform (Source Bioscience 
Sequencing, Cambridge, UK). Sequences were assem-
bled by using Chromas. 
2.4. Statistical analysis
We used SPSS 20 (SPSS Inc., Chicago, IL, USA) to 
analyze the obtained data. The genotype frequencies of 
OPRM, OPRD, and OPRK markers were compared be-
tween cases and controls through the single-locus case–
control test function in PowerMarker. 
3. Results
After separation of PCR products on 1% agarose gel, 
the bands were visualized by UV light. As shown in Fig-
ures 1, 2, and 3, the PCR products size were 301, 300, 
and 294 bp for OPRM, OPRK, and OPRD, respectively.
The results of automated DNA sequencing were assem-
bled by using Chromas (Table 2). Analysis of sequenc-
ing of OPRM showed no difference between the case 
and control group and the all of cases expressed the A 
nucleotide. Similar to OPRM, there was no variation 
in OPRK and OPRD sequencings. Finally, our results 
showed no association between heroin dependence and 
A118G, G36 T, and T921 C SNPs in the OPRM, OPRK, 
and OPRD, respectively. A possible explanation for 
these results may lie in the diversity of allele frequency 
across and within populations.
4. Discussion 
Addiction to drugs is influenced by physiological, psy-
chological, pharmacological, genetic and environmental 
factors. Furthermore, genetic parameters play an impor-
tant role in the pathogenesis of opioid addiction; heri-
tability nature of opioid abuse and or addiction ranges 
from 43% to 60% (Goldman, Oroszi, & Ducci, 2005; Li 
& Burmeister, 2009). Numerous lines of evidence has 
demonstrated a connection between opioid receptor vari-
ability and substance addiction in humans (Kowarik et 
al., 2012; Soto & Raingo, 2012). In this regard, Mayer et 
al. reported an association between DOR polymorphism 
and heroin dependence in men (Mayer et al., 1997). 
They showed that allele C was more frequent in Ger-
man Caucasian heroin addicts than in controls. Studies 
on experimental animals have shown that genetic poly-
morphisms in KORs play a role in having tendency to-
ward voluntary alcohol-drinking behavior (Saito et al., 
2003; Vadasz, Saito, Gyetvai, & Mikics, 2000). In ad-
dition, preliminary studies in humans revealed that 36 
G>T SNP on the KOR gene (hOPRK1) displays a strong 
association with A variety of addictive diseases (Yuferov 
et al., 2004). According to another study, heroin depen-
dency is shown to be correlated with a high frequency 
of allele 36 G>T SNP in the exon 2 of the human KOR 
gene (hOPRK1), proposing that the T allele might pre-
dispose people to addictive behavior or to personality 
traits at risk for substance abuse (Gerra et al., 2007). 
Table 1. List of primers in the study
Gene SNP Forward Primers Reverse Primers
OPRM A118G 5׳-GCTTGGAACCCGAAAAGTC-3׳ 5׳-GTAGAGGGCCATGATCGTGAT-3
OPRK G36T 5׳-CGTGCGCTGAGAGGCGGGGG-3 5׳-GCCGTGATGATGACCGGGATG-3
OPRD T921C 5׳- GGTGTGCATGCTCCAGTTCC-3 5׳-CGCGCCGGTCGATGTCCACC-3
Table 2. Sequencing of the genes 
SequencingGene
GCTTGGAACCCGAAAAGTCTCGGTGCTCCTGGCTACCTCGCACAGCGGTGCCCGCCCGGCCGTCAGTACCATGGACAGCAGCGCT-
GCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCAAGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTT-
GTCCCACTTAGATGGCAACCTGTCCGACCCATGCGGTCCGAACCGCACCGACCTGGGCGGGAGAGACAGCCTGTGCCCTCCGACCG-
GCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTAC
OPRM
AGTGGGAGACGTGCGCTGAGAGGCGGGGGCTGCGCTCGGCGGAACAGCAGCCCTCGGGCGGAGAGCGGGGCCGGGGTCCGAGA-
GCAGGTGATGCCAAGAGCTGAGCGGGACTCGTGAGCGCGCGGTTCAGCACCTACCAGGGCGTCCCGTAAAAAACCTCGCCTTCGCCT-
GTCTCTGGGAACCATAGGTAAGCTTTGGGCTTTCGAGGTGCAGTTCTAGGTAGAGCTCCGTGCTGGGAGGTGGGAAGGGGGCTT-
GACCCTGGGGACTCAGGCAGTCTGGG
OPRK
GGTGTGCATGCTCCAGTTCCCCAGCCCCAGCTGGTACTGGGACACGGTGACCAAGATCTGCGTGTTCCTCTTCGCCTTCGTGGTGCCCATCCT-
CATCATCACCGTGTGCTATGGCCTCATGCTGCTGCGCCTGCGCAGTGTGCGCCTGCTGTCGGGCTCCAAGGAGAAGGACCGCAGCCTGCG-
GCGCATCACGCGCATGGTGCTGGTGGTTGTGGGCGCCTTCGTGGTGTGTTGGGCGCCCATCCACATCTTCGTCATCGTCTGGACGCTGGTG-
GACATCGACCGGCGCG
OPRD
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Figure 1. OPRM gene expression on agarose 1% gel (301 bp)
Figure 2. OPRK gene expression on agarose 1% gel (300 bp)
Figure 3. OPRD gene expression on agarose 1% gel (294 bp)
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The present findings indicate no association between 
opioid dependency and novel polymorphisms A118G, 
36 G>T, 921C SNP in MOR, KOR, DOR genes, re-
spectively in contrast to the previously mentioned 
study. There are number of studies that consistent with 
our results. In this context, Bond and colleagues found 
no significant differences in A118G allele frequency 
between opioid dependent and non-dependent subjects 
with all ethnic groups combined (Bond et al., 1998). In 
another study on a European population, no significant 
association was shown between this SNP and opioid 
addiction (Beer et al., 2013). However in subgroup 
analysis by ethnicity, the A118G minor allele (G) fre-
quency was significantly higher in non-opioid depen-
dent Hispanic subjects (Bond et al., 1998). A study 
by Bart et al. also corroborated this association on a 
Swedish population of opiate-dependent and control 
subjects, demonstrating higher frequencies of the mi-
nor allele in opiate-dependent users (Bart et al., 2004). 
Study on MOR and KOR genes in Taiwanese popula-
tion revealed no significant differences in genotype fre-
quency or allele on subjects with alcohol dependency and 
controls (Loh, Fann, Chang, Chang, & Cheng, 2004). In 
addition, Franke et al. findings do not support the hy-
pothesis that the C allele elevates the risk of substance 
abuse, neither for alcohol dependence nor for heroin de-
pendence (Franke et al., 1999). In a European American 
population study by Zhang et al., no significant associa-
tion was shown between this SNP with alcohol, cocaine, 
and opioid dependence (Zhang, Kranzler, Yang, Luo, & 
Gelernter, 2007). In contrast to these reports, Mayer et 
al. showed that the abundance a silent T to C substitu-
tion in site 921 of the δ-opioid receptor gene was signifi-
cantly higher in heroin addicts than in control population 
(Mayer et al., 1997). The stressful events, personality 
disorders and negative emotional relationships, such as 
parent-child relationships, are considered predictors of 
addictive behaviors (Conner, Hellemann, Ritchie, & No-
ble, 2010). This is a good evidence for complex diseases 
where the genetic etiology is indicative of multifactorial 
syndrome. The genetic effects on any behavioral out-
come are influenced by exposure of individual to a cer-
tain environment. Thus, when interpreting the findings, 
interactions between environmental and genetic factors 
should be considered, for example, the tendency of indi-
viduals to purposefully adapt to specific environments. 
Our findings suggest that opioid receptor gene poly-
morphisms do not have a significant influence on the 
progress of heroin dependence among the Iranian pop-
ulation. Further studies are necessary to examine vari-
ables of opioid receptors genotype and its relation with 
individuals’ characteristics at risk to addictive behavior. 
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